iRhythm Approves Deferrals Of Up To 80% Of Salary — Participants Bear Creditor Risk

Eligible employees can defer all annual bonuses, but plan balances remain exposed to creditors if the company becomes insolvent.

Share
iRhythm Approves Deferrals Of Up To 80% Of Salary — Participants Bear Creditor Risk

iRhythm Holdings, which helps doctors diagnose irregular heart rhythms through wearable monitoring, approved a plan Wednesday allowing eligible employees to defer up to 80% of their base salary. The arrangement leaves participants with unsecured claims against the company, according to its SEC filing Friday.

Salary, Bonuses And Director Fees

The retirement-saving arrangement lets eligible employees postpone receiving pay and the income taxes associated with it. Eligibility includes iRhythm's named executive officers, who can elect to defer their entire annual bonus as well as salary within the plan's limit.

Eligible directors who are not employees can defer all their cash fees. iRhythm sponsors the plan, with its wholly owned subsidiaries iRhythm Technologies and Vital Connect participating.

Participants choose among investment options offered by the administrator. Their accounts track the gains and losses of those selections, which determine changes in the recorded balances.

The company can add matching payments or other contributions at its discretion. Any such additions can carry vesting requirements set by iRhythm—conditions participants must meet to earn those amounts.

The Trust Leaves Creditors' Claims Intact

The plan is unfunded: participants are owed money by iRhythm as unsecured general creditors. Their account balances therefore carry the company's credit risk.

That exposure would persist under the trust iRhythm intends to establish. If the company becomes insolvent, its creditors can make claims on the trust's assets.

Participants generally receive vested balances in one payment or yearly installments. They select the payment method when initially deferring the money, with later changes permitted under the plan's rules.

Zio's Wearable Monitoring Business

iRhythm's Zio system combines a wireless patch that records the heart's electrical activity for up to 14 days with cloud software that analyzes those recordings. Trained technicians review the resulting reports at Medicare-enrolled testing facilities before they reach prescribing doctors.

The company sells monitoring services mainly in the United States to physician practices and health systems, including cardiologists and primary care doctors. It also operates commercially in the United Kingdom, selected European countries and Japan.

The deferred-pay plan is scheduled to take effect January 1, 2027.

Sources

More on iRhythm Holdings

All iRhythm Holdings (IRTC) coverage →